A single 8-Gy dose of radiotherapy for painful bone metastases may improve quality of life and pain as early as 10 days after administration.
A new tool may enable oncologists to deliver radiation therapy targeted to a tumor's biology and radiosensitivity, similar to how anticancer agents target specific tumor mutation-affected gene pathways.
Progression-free survival with panitumumab plus accelerated-fractionation radiotherapy was compared with that of cisplatin plus standard-fractionation radiotherapy in patients with locoregionally advanced HNSCC in a recently published study.
Researchers report their study findings on the safety of omitting radiotherapy after breast-conserving surgery, sentinel node biopsy, and adjuvant endocrine therapy in older patients with early breast cancer and favorable histopathology at SABCS 2016.
Researchers report on the feasibility of a nurse-led sexual rehabilitation intervention to target sexual recovery and vaginal dilation in women who underwent pelvic radiation therapy and brachytherapy for gynecologic cancers.
IMRT was associated with lower rates of severe pneumonitis and cardiac doses compared with 3D-CRT in patients with locally advanced NSCLC.
Patients with early stage breast cancer who received breast-conserving surgery and were eligible for observation were more likely to undergo adjuvant radiotherapy in facilities performing APBI.
The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology have issued a joint consensus guideline update for the use of radiotherapy following mastectomy in patients with breast cancer.
Adding WBRT to dexamethasone and best supportive care provides little additional benefit for patients with NSCLC and brain metastases who are ineligible to undergo resection or stereotactic radiotherapy.
In contrast of available prospective data, most older patients with locoregionally advanced head and neck cancer are treated with definitive radiotherapy also receive systemic therapy.
Despite the use of adjuvant chemotherapy, deferral of postoperative radiotherapy is associated with worse survival in pediatric patients with medulloblastoma.
Functional status, a person's ability to perform normal activities of daily living, is associated with treatment choice for patients with prostate cancer.
Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed GlioblastomaJune 06, 2016
The addition of temozolomide to standard short-course radiation therapy significantly improved both overall and progression-free survival in elderly patients with newly diagnosed glioblastoma, results from the first study to test this combination in this age group concluded in a plenary presentation at the ASCO 2016 Annual Meeting.
Nimotuzumab + Radiotherapy Less Toxic Than Cisplatin + Radiotherapy for Stage III/IVB Nasopharyngeal CancerJune 05, 2016
Patients with locally advanced nasopharyngeal cancer concurrently treated with nimotuzumab and radiotherapy had similar rates of progression-free and overall survival to those treated with cisplatin and radiotherapy, but with significantly fewer GI and hematologic toxicities, according to phase 3 trial results presented at the ASCO 2016 Annual Meeting.
Survival results from the first randomized phase 3 trial to compare cisplatin-radiotherapy with cetuximab-radiotherapy after induction chemotherapy in patients with locally advanced unresectable head and neck cancer remain inconclusive, with both arms showing good locoregional control, greater than 50% at 3 years, attendees at the ASCO 2016 Annual Meeting were told.
Radiation therapy delivered to the critical vessels surrounding the prostate can result in erectile dysfunction and bladder and renal irritation. Vessel-sparing radiation and an improved understanding of the anatomy of the prostate can reduce these effects.
Training Patients With Breast Cancer to Achieve Prolonged Breath Holds Could Improve Targeted RadiotherapyMay 27, 2016
Patients with breast cancer can be trained to achieve a breath hold lasting more than 5 minutes, allowing for targeted administration of radiotherapy with a single dose per daily session that can minimize damage to surrounding tissues.
Radiotherapy in combination with anti-androgen hormone therapy halves the risk of death from prostate cancer 15 years after diagnosis compared with hormone therapy alone.
For women younger than 45 years with early stage breast cancer that has not spread to the lymph nodes, opting for breast-conserving therapy with RT was associated with higher risk of local recurrence over 20 years compared with mastectomy and no RT.
Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate CancerApril 22, 2016
Treatment with a hypofractionated radiotherapy (HRT) schedule achieved similar efficacy as treatment with the longer, conventional RT (CRT) schedule in men with low-risk prostate cancer.
A bladder preservation rate of 83% occurred at 3 years after a trimodality treatment approach for localized bladder cancer that used adaptive image-guided, intensity-modulated radiation therapy (IG-IMRT).
Nasal spray effectively relieves intense breakthrough pain associated with radiotherapy planning and treatment.
Partial breast radiotherapy was noninferior to whole breast radiotherapy in regard to local recurrence in women with low-risk early breast cancer.
A complex surgical procedure to remove the prostate achieves excellent long-term survival for men with prostate cancer after radiation therapy has failed.
Although reported absolute rates of second malignancies after radiotherapy for prostate cancer are very low, it is associated with higher rates of bladder, colon, and rectal cancers in patients who undergo radiotherapy for prostate cancer.
Adding panobinostat to radiotherapy appears safe, tolerable, and has preliminary efficacy for treating recurrent high-grade gliomas.
Limited radiotherapy effective after low-risk tumors are removed, but questions remain.
Sleep disturbances in patients with cancer preceded radiotherapy treatment and are associated with previous treatment, disease progression, and psychological symptoms.
As the American College of Surgeons' Commision on Cancer milestones approach, ASTRO publishes a template to ensure consistent, comprehensive survivorship care plans can be developed for cancer survivors whose treatment involved radiotherapy.
Posttreatment imaging at 3 months and physical examinations during the 6 months following treatment can detect most recurrences in patients treated with definitive radiation therapy for HPV-associated oropharyngeal cancer.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|